secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001193125-24-238959
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences: 4 of 5 low-grade NMIBC patients achieve clinical complete response with single-dose bel-sar
--------------------------------------------------------------------------------

- Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).
- 2 of 3 high-grade patients showed visual tumor shrinkage on cystoscopy; immune activation observed in all evaluable patients.
- Safety: only Grade 1 drug-related AEs in <10% of patients; no serious adverse events reported as of Sept 9, 2024 cutoff.
- Evidence of bladder urothelial field effect in non-target tumors, suggesting broader immune response.
- Company plans to expand Phase 1 and prepare for Phase 2 trial to evaluate durability of response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/0001193125-24-238959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312524238959/d818130d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-238959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer